CG Oncology, Inc.
$70.4
▲
1.03%
2026-04-21 06:00:02
cgoncology.com
NMS: CGON
Explore CG Oncology, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$6.2 B
Current Price
$70.4
52W High / Low
$73.56 / $19.47
Stock P/E
—
Book Value
$9.33
Dividend Yield
—
ROCE
-25.08%
ROE
-21.67%
Face Value
—
EPS
$-2.08
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
142
Beta
0.7
Debt / Equity
0.93
Current Ratio
24.63
Quick Ratio
24.58
Forward P/E
-33.98
Price / Sales
1,414.92
Enterprise Value
$4.98 B
EV / EBITDA
-26.31
EV / Revenue
1,232.95
Rating
Strong Buy
Target Price
$84.71
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Immatics N.V. | $11.25 | — | $1.51 B | — | -35.05% | -37.1% | $12.41 / $3.94 | $4.18 |
| 2. | Aprea Therapeutics, Inc. | $0.98 | — | $11.45 M | — | -100.49% | -74.58% | $2.22 / $0.55 | $1.52 |
| 3. | ImmunityBio, Inc. | $8.01 | — | $8.28 B | — | -58.17% | 71.02% | $12.43 / $1.83 | $-0.49 |
| 4. | Tonix Pharmaceuticals Holding Corp. | $14.34 | — | $184.59 M | — | -49.81% | -64.48% | $69.97 / $11.6 | $19.17 |
| 5. | Nektar Therapeutics | $100.35 | — | $2.87 B | — | -57.64% | -2.18% | $109 / $7.99 | $4.41 |
| 6. | Dyadic International, Inc. | $0.88 | — | $31.88 M | — | -114.18% | -3.98% | $1.35 / $0.65 | $0.03 |
| 7. | IGC Pharma, Inc. | $0.32 | — | $31.52 M | — | -114.73% | -83.34% | $0.5 / $0.24 | $0.09 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 2.32 M | 1.67 M | 0 M | 0.05 M | 0.46 M | — |
| Operating Profit | -48.7 M | -51.13 M | -48.74 M | -42.2 M | -38.05 M | — |
| Net Profit | -41.31 M | -43.81 M | -41.43 M | -34.45 M | -31.8 M | — |
| EPS in Rs | -0.49 | -0.52 | -0.49 | -0.41 | -0.38 | -0.3 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 4.04 M | 1.14 M | 0.2 M | 0.19 M |
| Operating Profit | -190.77 M | -114.67 M | -55.45 M | -35.25 M |
| Net Profit | -161 M | -88.04 M | -48.61 M | -35.44 M |
| EPS in Rs | -1.91 | -1.04 | -0.58 | -0.42 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 791.59 M | 754.8 M | 199.3 M | 147.75 M |
| Total Liabilities | 38.99 M | 21.42 M | 14.51 M | 22.57 M |
| Equity | 752.6 M | 733.38 M | 184.79 M | 125.18 M |
| Current Assets | 759.48 M | 754.21 M | 194.12 M | 147.21 M |
| Current Liabilities | 30.84 M | 21.37 M | 14.25 M | 15.43 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -132.35 M | -78.71 M | -45.68 M | -29.8 M |
| Investing CF | -245.82 M | -300.76 M | -121.19 M | -55.35 M |
| Financing CF | 153.59 M | 628.28 M | 87 M | 119.69 M |
| Free CF | -132.48 M | -78.95 M | -45.68 M | -29.82 M |
| Capex | -0.13 M | -0.23 M | — | -0.01 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 458.33% | 6.81% | — | — |
| Earnings Growth % | -81.12% | -37.14% | — | — |
| Profit Margin % | -7729.5% | -23826.96% | -18556.54% | — |
| Operating Margin % | -10067.25% | -27180.88% | -18453.4% | — |
| Gross Margin % | 100% | 100% | — | — |
| EBITDA Margin % | -10064.44% | -27172.55% | -18445.55% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.